Related Experiment Video
Updated: Jan 5, 2026
In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's
Jessica K Ortwine1,2, Evan J Zasowski3,4, Jason M Pogue5,6
1Department of Pharmacy Services, Parkland Health and Hospital System, Dallas, TX, USA.
Introduction:
A one-time vancomycin loading dose of 25-30 mg/kg is recommended in the current iteration of the vancomycin consensus guidelines in order to more rapidly achieve target serum concentrations and hasten clinical improvement. However, there are few clinical data to support this practice, and the extents of its benefits are largely unknown.
Methods:
A multicenter, retrospective, cohort study was performed to assess the impact of a vancomycin loading dose (≥ 20 mg/kg) on clinical outcomes and rates of nephrotoxicity in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. The study matched patients in a 1:1 fashion based on age, Pitt bacteremia score, and bacteremia source. The primary outcome was composite treatment failure (30-day mortality, bacteremia duration ≥ 7 days after vancomycin initiation, persistent signs and symptoms of infection ≥ 7 days after vancomycin initiation, or switch to an alternative antimicrobial agent). Secondary outcomes included duration of bacteremia, length of stay post-bacteremia onset, and nephrotoxicity.
Results:
A total of 316 patients with MRSA bacteremia were included. Median first doses in the loading dose and non-loading dose groups were 23.0 mg/kg and 14.3 mg/kg, respectively (P < 0.001). No difference was found in composite failure rates between the non-loading dose and loading dose groups (40.5% vs. 36.7%; P = 0.488) or in the incidence of nephrotoxicity (12.7% vs. 16.5%; P = 0.347). While multivariable regression modeling showed receipt of a vancomycin loading dose on a mg/kg basis was not significantly associated with composite failure [aOR 0.612, 95% CI (0.368-1.019)]; post hoc analyses demonstrated that initial doses ≥ 1750 mg were independently protective against failure [aOR 0.506, 95% CI (0.284-0.902)] without increasing the risk for nephrotoxicity [aOR 0.909, 95% CI (0.432-1.911)].
Conclusion:
These findings suggest that initial vancomycin doses above a certain threshold may decrease clinical failures without increasing toxicity and that weight-based dosing might not be the optimal strategy.
Insights
A vancomycin loading dose of 25-30 mg/kg is recommended but lacks clinical data. This study found that while weight-based dosing showed no benefit for MRSA bacteremia, fixed doses ≥1750 mg reduced treatment failures without increasing nephrotoxicity.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Current vancomycin consensus guidelines recommend a 25-30 mg/kg loading dose to rapidly achieve therapeutic concentrations.
- Limited clinical data exist to support the efficacy and safety of this weight-based loading dose strategy.
- The benefits and potential risks associated with vancomycin loading doses require further investigation.
Purpose of the Study:
- To evaluate the impact of a vancomycin loading dose (≥20 mg/kg) on clinical outcomes in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.
- To assess the association between vancomycin loading doses and the incidence of nephrotoxicity.
- To compare composite treatment failure rates between patients receiving and not receiving a vancomycin loading dose.
Main Methods:
- A multicenter, retrospective cohort study involving 316 patients with MRSA bacteremia.
- Patients were matched 1:1 based on age, Pitt bacteremia score, and bacteremia source.
- Primary outcome was composite treatment failure; secondary outcomes included bacteremia duration and nephrotoxicity.
Main Results:
- No significant difference in composite failure rates (36.7% vs. 40.5%) or nephrotoxicity (16.5% vs. 12.7%) was observed between loading dose and non-loading dose groups.
- Multivariable analysis indicated that weight-based vancomycin loading doses were not significantly associated with reduced composite failure.
- Post hoc analysis revealed that initial vancomycin doses ≥1750 mg were independently protective against treatment failure without increasing nephrotoxicity risk.
Conclusions:
- Initial vancomycin dosing strategies may need re-evaluation, as weight-based dosing did not demonstrate significant clinical benefits.
- Achieving a specific total initial vancomycin dose (e.g., ≥1750 mg) might be more critical for reducing treatment failures than weight-based calculations.
- Higher fixed initial vancomycin doses may offer improved clinical outcomes in MRSA bacteremia without a corresponding increase in nephrotoxicity.
More Related Videos
Related Concept Videos
01:20Estimation of k and VD of Aminoglycosides
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions